Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1 effectively blocked tumor growth in five patients with neuroendocrine cancer and reduced tumor size in two of them in clinical trials, while also showing some therapeutic activity against sarcomas. PAC-1, a drug that stimulates programmed cell death in cancer cells, was found in phase I clinical trials to have only mild side effects in patients with advanced cancer.

Pre: adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

Next: The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca